Regulatory Filing in Pharma: How to Develop One Drug for Global Markets – US, EU, and ROW
- What is Regulatory Filing? Why It Is Needed
- Regulated vs Emerging (ROW) Markets – Difference
- Driving Force for Harmonization – ICH, WHO ICDRA
- Regulatory Strategy – Why It Must Come Before Development
- Generic Drug Opportunity – $150 Billion Patent Cliff
- Components of Regulatory Filing & Dossier Submission
- How Indian Pharma Can Plan Global Filing
1. What is Regulatory Filing?
Pharma is one of the most highly regulated industries in world, with many rules enforced by government to protect health and well-being of public.
Regulatory filing is the process of submitting technical documentation (dossier) to regulatory authority to get permission to market a drug in that country.
Role of regulatory authority is to ensure quality, safety, and efficacy of all medicines in circulation. It not only includes process of regulating and monitoring drugs but also process of manufacturing, distribution, and promotion.
One of primary challenges for regulatory authority is to ensure pharmaceutical products are developed as per regulatory requirement of that country. This involves assessment of critical parameters during product development.
Regulatory guidelines and standard tools provide basis for implementation of laws, whereas laws provide legal basis for drug control. World covers more than 100 countries, where most have established legislations and regulatory requirements. For worldwide dossier submissions, it is pre-requisite to have knowledge of country-specific guidelines and norms.
Therefore, it is very important to analyze differences and commonness between regulatory requirements of different countries.
2. Regulated vs Emerging Markets – Where to File?
Based on diversity in regulation and marketing interest, pharma market can be divided into two groups:
| Market Type | Countries | Regulatory Body | Dossier Format | Nature |
|---|---|---|---|---|
| Regulated Markets – Biggest & Most Potential | US, EU (27 countries), Japan, Canada, Australia | USFDA, EMA, PMDA, Health Canada, TGA | Strict CTD / eCTD, Full ICH Guidelines | Well defined, stringent, harmonized, data intensive |
| Emerging / ROW Markets – Rest of World | Brazil (LATAM), Mexico, Tanzania & Kenya (Africa), Russia & CIS, India, China, Hong Kong, ASEAN, GCC, etc. | ANVISA, COFEPRIS, TFDA, Roszdravnadzor, DCGI/CDSCO, NMPA, etc. | Country-specific, often CTD but with local requirements, Some still ACTD | Evolving, less defined, price sensitive, faster growth |
US and EU are biggest markets and categorized under regulated markets, whereas ROW market includes all emerging markets like Brazil (LATAM), Tanzania (Africa), Russia (CIS), Hong Kong (ASIA), etc.
Practical Difference I see: US needs ANDA with BE against RLD, detailed QbD, DMF. EU needs MAA via DCP/MRP/Centralised, needs CEP, EDQM compliance. Brazil (ANVISA) needs GMP certificate from ANVISA audit + Portuguese labeling + local stability Zone IVb. Tanzania (TMDA) needs WHO-type CTD + Zone IVb stability + CPP. So same product but dossier must be tailor-made.
3. Why Harmonization Was Needed – Birth of ICH
After introduction of product patent regime in India, there was need for pharma companies both in India and abroad to explore newer markets. Indian pharma majors are entering new markets with global ambitions, mergers and acquisitions are in focus to enter new market.
For sustained growth, firms have to concentrate on generic drug products. “Diseases that cannot be cured, diseases that have to be managed, provide great opportunities for generic drugs.”
Somewhat parallel with ongoing harmonization and movement toward creating common market for medicines inside EU, need for wider harmonization was felt by officials from Japan, EU, and US during International Conference of Drug Regulatory Authorities (ICDRA) organized by WHO.
Efforts to harmonize various elements of drug regulatory activities have been initiated by various inter-governmental organizations at regional and inter-regional level in past decade. Driving force behind these efforts has been increase in global trade in pharmaceutical products, and growth in complexity of technical regulations related to drug efficacy, safety, and quality.
International Council for Harmonisation (ICH) came with common guidelines – Q (Quality), S (Safety), E (Efficacy), M (Multidisciplinary). Biggest gift is CTD – Common Technical Document – Same structure for US, EU, Japan. CTD has 5 Modules:
Module 1: Regional administrative info
Module 2: Quality Overall Summary
Module 3: Quality (CMC)
Module 4: Non-clinical
Module 5: Clinical
Now eCTD is mandatory for regulated markets. ROW markets also slowly adopting CTD.
4. Generic Opportunity – $150 Billion Patent Cliff
As per global market trend, it was estimated that approximately $150 billion worth of drugs will be off-patented during period 2010 to 2017, which served as platform for pharma companies to develop generic drugs. Same wave continues now 2024-2030 with many biologics going off-patent.
Aim of pharma industry is to identify and develop generic drug product which can be tailor-made to meet diverse market requirements. You cannot make one generic and submit everywhere. You need to tailor – API source, polymorphic form, excipient compliance (e.g., EU needs TSE/BSE free), stability zones, bio-study against local RLD, labeling language.
5. Regulatory Strategy – Must Be Established BEFORE Development
Regulatory requirements of various countries vary from each other. Therefore, it is challenging to develop single drug which can be simultaneously submitted in all countries for approval.
The regulatory strategy for product development is essentially to be established before commencement of developmental work in order to avoid major surprises after submission of application.
1. Target markets? US + EU + Brazil + Africa?
2. What is RLD in each market? Different RLD – different BE study needed
3. Stability Zone – US/EU Zone II, Brazil/Tanzania Zone IVb (30°C/75% RH) – Need to plan stability upfront
4. API DMF/CEP – US needs US DMF, EU needs CEP or EU DMF, ROW may need both
5. Excipient – EU needs Ph.Eur, US USP, plus TSE/BSE, GMO free statements
6. Bioequivalence – Fasting vs fed, strength, local CRO requirement for ROW?
7. Dossier format – eCTD for US/EU, CTD for ROW with Module 1 country-specific
8. Manufacturing – GMP certificates needed – ANVISA GMP, EU GMP, WHO GQ?
9. Labeling – Language, artworks, patient info leaflet requirements
10. Patent – Patent status in target country, Paragraph IV for US?
If you start formulation without answering these, you will redo stability, redo BE, redo documentation – Waste of 12-18 months and crores.
6. Components of Regulatory Filing
Fig. Components of Regulatory Filing
Active Pharmaceutical Ingredient (API) → Finished Product Development (QbD, Formulation) → Analytical Method Validation → Stability Studies (ICH Q1A) → Bioequivalence Studies → Manufacturing & GMP Compliance → Packaging & Labeling → CTD Dossier Compilation → Submission to Authority → Review & Queries → Approval & Post-Approval Life Cycle Management
Detailed Components as per CTD:
- Module 1 – Administrative: Application form, cover letter, labeling, patent declaration, GMP certificates, Letter of authorization for DMF/CEP, SmPC, PIL
- Module 2 – Summaries: QOS – Quality Overall Summary, Non-clinical and Clinical Overviews
- Module 3 – Quality: Most critical for generics – 3.2.S Drug Substance (API manufacturer, characterization, impurities, control, stability), 3.2.P Drug Product (Description, composition, pharmaceutical development – QbD, manufacture, excipient controls, control of product, stability Zone II/IVb)
- Module 4 & 5 – For generics: Module 4 not needed, Module 5 contains Bioequivalence study reports, bioanalytical validation
7. How to Plan Filing for Different Markets – My Practical Approach
| Parameter | US (USFDA) | EU (EMA) | ROW – Brazil / Tanzania / Russia |
|---|---|---|---|
| Application Type | ANDA (505j) | MAA – DCP / MRP / Centralised | Marketing Authorization – Generic |
| Stability | Zone II – 25°C/60% RH, 12 months long term | Zone II – 25°C/60% RH | Zone IVb – 30°C/75% RH, Brazil needs 12 months + photo |
| BE Study | Against US RLD, USFDA BE Guidance | Against EU Reference, EMA BE Guidance | Often against local RLD, ANVISA requires local BE for many products |
| GMP Requirement | USFDA inspection | EU GMP certificate | ANVISA GMP inspection mandatory for Brazil, TMDA for Tanzania |
Conclusion
Regulatory filing is not just documentation. It is strategy. World has 100+ countries, each with own legislations. If you try to make one dossier for all, you will fail. If you plan strategy before development – choose target markets, understand CTD vs local requirements, stability zones, BE requirements, GMP needs – then you can develop tailor-made product that can be submitted globally with minimal rework.
Regulated markets give high value but need high quality data and eCTD. ROW markets give volume and growth but need local understanding. Best approach for Indian pharma – Develop product as per most stringent market (US/EU), with Zone IVb stability, so you can use same data for ROW filing also. This is what I call “One Development, Global Filing” approach.
Remember – Regulatory guidelines provide basis for implementation of laws, laws provide legal basis for drug control. Knowledge of country-specific guidelines is pre-requisite for worldwide dossier submission.
The information provided on this page is for educational and informational purposes only. It is not intended to provide regulatory, legal, or compliance advice.
Pharmaceutical regulations including FDA 21 CFR, EU GMP Annexes, ICH Guidelines, EDQM, WHO, and CDSCO requirements are subject to frequent updates and interpretation by regulatory authorities.
Readers are responsible for ensuring compliance with current applicable laws and regulations in their jurisdiction. PharmaShare does not guarantee the accuracy, completeness, or currentness of this content.
This content does not create a consultant-client relationship. For product-specific regulatory strategy, dossier preparation, or inspection readiness, please consult qualified regulatory professionals or contact us directly.
About the Author
Mahummed Asif is a experienced pharmaceutical Quality Assurance professional and publisher of Pharmashare. He has worked with leading Pharmaceutical organizations and has developed extensive expertise in Quality Assurance, deviation management, investigations, CAPA, QMS, Product Life Cycle Management, change control, risk management, validation, product complaints, product recalls, and regulatory compliance. He is passionate about sharing practical pharmaceutical knowledge with professionals, students, and quality practitioners across the industry.